Detalhe da pesquisa
1.
Severe hepatotoxicity during treatment with capmatinib.
J Oncol Pharm Pract
; 29(6): 1484-1488, 2023 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-37157816
2.
Adherence and quality of life in patients with chronic lymphocytic leukemia treated with oral antineoplastic drugs. / Adherencia y calidad de vida en los pacientes con leucemia linfocítica crónica tratados con antineoplásicos orales.
Farm Hosp
; 47(2): 69-74, 2023.
Artigo
em Inglês, Espanhol
| MEDLINE | ID: mdl-36599751
3.
[Translated article] Adherence and quality of life in patients with chronic lymphocytic leukemia treated with oral antineoplastic drugs.
Farm Hosp
; 47(2): T69-T74, 2023.
Artigo
em Inglês, Espanhol
| MEDLINE | ID: mdl-36697340
4.
Predictive value of immune-related adverse events during pembrolizumab treatment in non-small cell lung cancer.
Eur J Hosp Pharm
; 2022 Apr 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-35383033
5.
Adherencia y calidad de vida en los pacientes con leucemia linfocítica crónica tratados con antineoplásicos orales / Adherence and quality of life in patients with chronic lymphocytic leukemia treated with oral antineoplastic drugs
Farm. hosp
; 47(2): 69-74, marzo-abril 2023. tab
Artigo
em Espanhol
| IBECS (Espanha) | ID: ibc-218917